These are concerns of mine as well. The cost of operations are extremely high and the cost of sales are high.
The one mitigating factor is that they are not selling individual products, they are basically subscriptions.
Each sale of the box gives them potentially years and years of buying carts for the machine. Sales doesn't have to cold call new customers to replicate past sales, the simply need to find new ones.
As the FDAs are approved, the device gets more use and more carts can be sold. Most of the sales to this point were based on a single test, and now there are 4. That means that the potential profit from each installation is 4 times what it was initially. With more offerings, there are also more opportunities to sell. In short, there is a lot of synergy between sales and development.
When I owned a newspaper,it was hard to make most ad salesmen unserstand that you aren't just selling this ad, you are selling the next one and the next. So, they might have sold a $100 ad, but if it is run every week, their commition is on $5,200 a year. Still, it was tough to find salemen, because they didn't want to build a portfolio, they wanted salary upfront. This company's sales model.is similar.
So, my gamble is twofold. The technology is like worth much more than the current MC, assuming no runaway dilution and simply normal growtg in shares to raise capital.
The second is that the sales growth will be slightly exponential as products come on line. You'll have the current customers, plus new customers multuplied by 4,5,6, etc products.
